Raija Lithovius

Raija Lithovius

Auto-generated profile, based on publicly available information

Raija Lithovius

Folkhälsan Research Center, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2024 in Diabetic Medicine
Verified
Journal Article
Open access
FSFanny Jansson Sigfrids
Fanny Jansson Sigfrids
RLRaija Lithovius
Raija Lithovius
PGPer-Henrik Groop
Per-Henrik Groop
LTLena M. Thorn
Lena M. Thorn
Aims: Across its operational span of more than 25 years, the observational, nationwide, multicentre Finnish Diabetic Nephropathy (FinnDiane) Study has aimed to unravel mechanisms underlying diabetic kidney disease, with a special focus on its metabolic risk factors. We sought to compile key findings relating to this topic and to offer a current perspective on the natural course of diabetic kidney disease among individuals with type 1 diabetes.Methods: In this narrative review, articles relevant to the subject published by the FinnDiane Study were identified and summarized together with work published by others, when relevant.Results: The FinnDiane Study has underscored the significance of dysglycaemia and insulin resistance, increased visceral fat mass, hypertension and dyslipidaemia—particularly high triglycerides and remnant cholesterol—as risk factors for diabetic kidney disease. Factors like abdominal obesity seem to influence the early stages of the disease, while the presence of the metabolic syndrome becomes implicated at later stages. Epidemiological reports have revealed that after an initial decline, the cumulative incidence of albuminuria plateaued post‐1980s, with the progression rate to kidney failure remaining high. Fortunately, 23% of the FinnDiane cohort regressed to less advanced stages of albuminuria, improving their overall prognosis.Conclusion: A substantial burden of albuminuria associated with type 1 diabetes persists, and therefore, novel kidney‐protecting therapies are highly awaited. In addition, given that metabolic factors influence the progression of diabetic kidney disease both in its early and advanced stages, emphasis should be placed on ensuring that their treatment targets are met.

27 July 2024 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
RLRaija Lithovius
Raija Lithovius
SMStefan Mutter
Stefan Mutter
EPErika B. Parente
Erika B. Parente
VHValma Harjutsalo
Valma Harjutsalo
PGPer-Henrik Groop
Per-Henrik Groop
Aims: We estimated overall refill adherence to all antihypertensive [AHT] and/or lipid-lowering drugs in the treatment regimen and its association with cardiovascular disease (CVD) in adults with type 1 diabetes, taking kidney disease into account. Methods: This Finnish Diabetic Nephropathy Study involved 1,558 adults with type 1 diabetes who had purchased AHT and/or lipid-lowering drugs within +/- 0.5 year from baseline and were followed until their first CVD event, death, or end of 2015. Proportion of days covered (PDC) method was used to calculate adherence. The adherence was classified as good (>= 80 %), intermediate (>= 50 and <80%) or poor (<50%). Results: Median adherence rate was 74% (IQR 63-84 %). Both good (OR 0.55 [95% CI 0.33, 0.92], P=0.02) and intermediate (0.47 [0.29, 0.77], P=0.003) adherence were associated with lower odds of CVD, compared to poor adherence. Moreover, the higher the adherence percentage point in those with moderate albuminuria, the lower was the odds for CVD (0.81 [0.67, 0.98], P=0.03, per 10 unit increase in adherence). Conclusions: In adults with type 1 diabetes, refill adherence of 50% or more to cardio-protective medications is associated with lower odds of incident CVD. Our findings highlight the relevance of going beyond prescribing protective CVD drugs, ensuring, and improving medication adherence matters.

18 November 2025 in Acta Diabetologica
Verified
Journal Article
Open access
PDF file
RLRaija Lithovius
Raija Lithovius
SMStefan Mutter
Stefan Mutter
EPErika B. Parente
Erika B. Parente
VHValma Harjutsalo
Valma Harjutsalo
PGPer-Henrik Groop
Per-Henrik Groop
NSNiina Sandholm
Niina Sandholm
Aims: To investigate the association between depression and refill adherence to cardioprotective medications in a representative cohort of type 1 diabetes adults. Methods: This Finnish Diabetic Nephropathy (FinnDiane) sub-study included 1,588 adults with type 1 diabetes who had purchased antihypertensive or lipid-lowering drugs within ± 0.5 years from study baseline. The proportion of days covered (PDC) method was used to calculate overall refill adherence over a 10-year follow-up. Adherence was classified into good (> 80%), intermediate (≥ 50 and < 80%), and poor (< 50%). Participants were considered to have depression, if they had a diagnosis of depression or had purchased antidepressive agents at any time point from 1995 until the end of follow-up, identified from national registries. Multinomial logistic regression analysis, adjusted for age, sex, duration of diabetes, education level, HbA 1c , BMI, diabetic kidney disease, smoking, and alcohol consumption was performed. Results: Of the cohort 37% had depression during the study period. Those individuals with depression were more often women ( P = 0.0001), and had lower adherence to cardioprotective medication ( P = 0.02) than those without depression. Individuals with depression had 72% higher odds ([95% CI 1.09, 2.70], P = 0.02) of having poor versus good adherence, compare to those without depression. The results persisted after excluding antidepressants potentially used for neuropathic pain (OR 1.61 [95% CI 1.02, 2.55], P = 0.04). Conclusions: Healthcare professionals should assess presence of depression and monitor medication adherence at regular consultations, and whenever needed, should implement strategies to manage the depression in order to enhance adherence, which might ultimately lead to improved cardiovascular outcomes in type 1 diabetes.

23 December 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
AKAnmol Kumar
Anmol Kumar
SMStefan Mutter
Stefan Mutter
EPErika B. Parente
Erika B. Parente
VHValma Harjutsalo
Valma Harjutsalo
RLRaija Lithovius
Raija Lithovius
PGPer-Henrik Groop
Per-Henrik Groop
Objective: Vascular endothelial growth factor (VEGF) plays a key role in diabetic retinopathy (DR). L-type calcium channel blockers (LTCCBs) have been widely used as antihypertensive medication (AHM), but their association with VEGF and DR is still unclear. Therefore, we explored the effect of LTCCBs compared to other AHMs on VEGF concentrations in retinal cells and human serum. Furthermore, we evaluated the association between the use of LTCCBs and the risk of severe diabetic eye disease (SDED). Research design and methods: Müller cells (MIO-M1) were cultured as per recommended protocol and treated with LTCCBs and other AHMs. VEGF secreted from cells were collected at 24 hours intervals. In an interventional study, 39 individuals received LTCCBs or other AHM for four weeks with a four-week wash-out placebo period between treatments. VEGF was measured during the medication and placebo periods. Finally, we evaluated the risk of SDED associated with LTCCB usage in 192 individuals from the FinnDiane Study in an oberservational setting. Results: In the cell cultures, medium VEGF concentration increased time-dependently after amlodipine (p0.01), or lisinopril (p>0.01). Amlodipine, but no other AHM, increased serum VEGF concentration (p<0.05) during the interventional clinical study. The usage of LTCCB was not associated with the risk of SDED in the observational study. Conclusions: LTCCB increases VEGF concentrations in retinal cells and human serum. However, the usage of LTCCBs does not appear to be associated with SDED in adults with type 1 diabetes.